NSE · BETA
Beta Drugs Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹58 Cr with net profit ₹4 Cr — a 6.4% net margin, versus 10.62% the period before.
Shareholding
As of 2026-09-30
- Promoter58.91%
- Public33.27%
- FII1.37%
- DII6.45%
10,145 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.84× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #8 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,73,977 Cr | 91.96 | 16.32 | 15.32% | 26.05% |
| Acutaas Chemicals Limited | ₹31,001 Cr | 70.59 | 16.69 | 23.64% | 27.58% |
| Neuland Laboratories Ltd. | ₹25,275 Cr | 55.85 | 12.46 | 22.3% | 19.61% |
| Jubilant Pharmova Ltd. | ₹14,966 Cr | 38.57 | 2.11 | 5.62% | 4.11% |
| SMS Pharmaceuticals Ltd. | ₹4,669 Cr | 39.92 | 5.54 | 13.88% | 12.04% |
| Aarti Drugs Ltd. | ₹4,077 Cr | 17.7 | 2.42 | 13.61% | 8.03% |
| Hikal Limited | ₹2,707 Cr | 38.05 | 2.25 | 3.03% | -27.19% |
| Beta Drugs Limited(this company) | ₹2,008 Cr | 38.69 | 4.59 | 11.86% | 11.69% |
| NGL Fine Chem Limited | ₹1,750 Cr | 30.6 | 5.27 | 14.62% | 10.67% |
| Fermenta Biotech Ltd. | ₹1,314 Cr | 24 | 3.14 | 12.29% | 10.01% |
AI analysis
AI-generated · google/gemini-2.5-flashBeta Drugs Limited is listed with a market capitalization of Rs 2473 Cr. The company reported revenue of Rs 368.79 Cr with a profit margin of 10.78%. Earnings per share (EPS) stood at Rs 44.97.
Positives
- +Revenue growth was 22.5%, indicating an increase in sales.
- +The debt-to-equity ratio is 0.43, suggesting a modest level of debt.
- +Return on capital employed (ROCE) is 17.4555%, indicating efficient use of capital.
Negatives
- −The trailing twelve months PE ratio is 273.17, which is high.
- −The company has not disclosed quarterly results since March 2026.
- −FII shareholding declined from an unspecified amount in Aug 2017 to 2.9542% in May 2026.
- −Despite having quarterly results in 2025 and 2026, the EPS for these periods is not provided.
Financial Performance
Beta Drugs Limited achieved revenue of Rs 368.79 Cr, representing a growth of 22.5%. The company's profit margin was 10.78%, leading to an EPS of Rs 44.97. Return on equity (ROE) was 16.95% and return on capital employed (ROCE) was 17.4555%.
Profitability & Returns
The company recorded a profit margin of 10.78%. Return on equity (ROE) was 16.95% and return on capital employed (ROCE) was 17.4555%. The PE ratio stands at 273.17.
Balance Sheet
The company has a debt-to-equity ratio of 0.43. The book value per share is Rs 241.46.
Ownership & Pledges
DIIs held 6.0148% and FIIs held 2.9542%. The public shareholding was 31.9342%. There are no reported promoter share pledges.
Regulatory & Surveillance
There is no information provided regarding the company's inclusion on any surveillance lists.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.